yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica NV and receives EUR4 million milestone payment

MECHELEN, BELGIUM -- (Marketwire) -- 01/16/13 -- Galapagos NV (Euronext: GLPG) announced today that it has identified a second pre-clinical compound in its alliance with Janssen Pharmaceutica NV. This achievement triggered a milestone payment of EUR4 million to Galapagos.

In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing it with option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs. The milestone announced today relates to the delivery of a second pre-clinical candidate developed by Galapagos.

"We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen," said Onno van de Stolpe, CEO of Galapagos. "Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs."

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with a novel mode-of-action. The Company is progressing four clinical, six pre-clinical, and 30 discovery programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. Its lead program is GLPG0634, an orally-available, selective inhibitor of JAK1, for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement in the signs and symptoms of rheumatoid arthritis and a unique safety profile. A 6 month Phase 2b study is expected to start Q2 2013 with top line data expected in Q4 2014. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos is also progressing two other clinical development programs with clinical readouts expected in 2013: GLPG0187, a novel integrin receptor antagonist in development for metastasis, is in a Phase 1b patient study; GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD. This program is in a second Phase 1 study and will start a Proof of Concept Phase 2 study in Q2 2013. The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information about the company and its drug development programs can be found online at:

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE


Galapagos NV
Onno van de Stolpe
Tel: +31 6 2909 8028

Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
I have three words for everyone in software testing: prioritize, prioritize, and prioritize. You can't test every possible permutation of your software, especially so with APIs and IoT devices where you're placing much of the user experience in the hands of integrators to your core pro...
Recently announced Azure Data Lake addresses the big data 3V challenges; volume, velocity and variety. It is one more storage feature in addition to blobs and SQL Azure database. Azure Data Lake (should have been Azure Data Ocean IMHO) is really omnipotent. Just look at the key capabi...
CodeBug is a cute, programmable and wearable device designed to introduce simple programming and electronic concepts to anyone, at any age. It is easy to program CodeBug using the online interface, which features colourful drag and drop blocks, an in-browser emulator and engaging commu...
Azure IoT Suite became Generally Available starting September 29. This suite consist of technologies to monitor and manage devices that come under Internet of Things. Microsoft according to Scott Guthrie provides advanced capabilites like stream processing and predictive analytics. En...
Scott Guthrie's keynote presentation "Journey to the intelligent cloud" is a must view video. This is from AzureCon 2015, September 29, 2015 I have reproduced some screen shots in case you are unable to view this long video for one reason or another. One of the highlights is 3 data...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers